Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy.
A number of novel serotonergic antidepressants have been introduced to clinical practice over the last decade. These medications are felt to be safe alternatives to the traditional tricyclic antidepressants and monoamine oxidase inhibitors, particularly in the overdose setting. Serious adverse reactions and drug interactions have been appreciated and fatalities have been reported. We describe the development of the serotonin syndrome in a 60 year old female on chronic tranylcypromine treatment following the inadvertent ingestion of a single dose of venlafaxine. Manifestations included and altered mental status that progressed to hyperthermia and coma. She recovered quickly and without complications. Health care providers and poison specialists need to be aware that this potentially serious syndrome can be precipitated by a single dose of a serotonin reuptake inhibitor in patients being treated with a monoamine oxidase inhibitor.
Hodgman
M J
MJ
Department of Emergency Medicine, St Joseph Hospital, Bangor, Maine, USA.
Martin
T G
TG
Krenzelok
E P
EP
D018687:Antidepressive Agents, Second-Generation / Q000506:poisoning*; D003128:Coma / Q000139:chemically induced; D003511:Cyclohexanols / Q000506:poisoning*; D004347:Drug Interactions; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000506:poisoning*; D013577:Syndrome; D014191:Tranylcypromine / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D014191:Tranylcypromine; D000069470:Venlafaxine Hydrochloride